Superworth

Moderna EPS MRNA

Diluted earnings per share by quarter and over the last twelve months, from 2018.

Last 12 months, to Jun 30, 2026
−$7.99
Latest quarter, Q2 FY26
−$1.97
Fiscal year 2025
−$7.27

Moderna's earnings per share was −$7.99 over the twelve months to Jun 30, 2026.

In its latest quarter, Q2 FY26, it was −$1.97.

Earnings per share over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearEPSChange
FY2025−$7.27n/a
FY2024−$9.26n/a
FY2023−$12.39−162%
FY2022$19.95−29%
FY2021$28.29n/a
FY2020−$1.94n/a
FY2019−$1.55n/a
FY2018−$5.05n/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedEPSOn a year earlierLast 12 months
Q2 FY26−$1.97n/a−$7.99
Q1 FY26−$3.40n/a−$8.15
Q4 FY25−$2.11n/a−$7.27
Q3 FY25−$0.51−1800%−$8.05
Q2 FY25−$2.13n/a−$7.51
Q1 FY25−$2.52n/a−$8.71
Q4 FY24−$2.89−607%−$9.26
Q3 FY24$0.03n/a−$5.80
Q2 FY24−$3.33n/a−$15.36
Q1 FY24−$3.07−1716%−$15.65
Q4 FY23$0.57−84%−$12.39
Q3 FY23−$9.53−477%−$9.36

Against its peers

Companies in Biotechnology nearest Moderna's size, closest first, today.

CompanyEPS, 12 monthsGrowth
MRNAModerna−$7.99
REGNRegeneron Pharmaceuticals$40.44+2% a year
VRTXVertex Pharmaceuticals$17.18+23% a year
ONCBeOne Medicines$0.43
ALNYAlnylam Pharmaceuticals$5.93
UTHRUnited Therapeutics$27.95+9% a year
INCYIncyte$7.85+78% a year
EXELExelixis$3.18+53% a year
NBIXNeurocrine Biosciences$6.82+102% a year
HALOHalozyme Therapeutics$3.35−23% a year
TECHBIO-TECHNE$1.15+150% a year
Peer median$6.38

What the EPS figure tells you

Net income divided by diluted shares. The denominator of PE.

One-off charges and gains swing it. The TTM view smooths a single odd quarter.

More on Moderna

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.